Summary Sixty-three patients with extensive-stage small-cell lung cancer were randomized to receive either cyclophosphamide, vincristine, doxorubicin and etoposide (CODE) alone or CODE plus recombinant human granulocyte colony-stimulating factor (rhG-CSF). rhG-CSF administration in support of CODE chemotherapy resulted in increased mean total received dose intensity for all drugs (P = 0.03) with a significant improvement in survival (P= 0.004).
PATIENTS AND METHODS
Between May 1989 and September 1991, 63 consecutive eligible patients with extensive-stage SCLC were treated at the Osaka Prefectural Habikino Hospital and the National Kinki Central Hospital.
The criteria for entry included histological or cytological proof of SCLC, extensive-stage disease including ipsilateral pleural effusion, measurable disease or evaluable disease, no prior therapy, life expectancy of 2 8 weeks, performance status of 0-2 (ECOG scale), age of 18-75 years, adequate bone marrow reserve, normal hepatic and renal functions, no active concomitant malignant disease and the written informed consent of the patient. Clinical features at diagnosis, staging procedures and the criteria used to assess the response to treatment have been described elsewhere (Masuda et al, 1992; Fukuoka et al, 1994) . The CODE combination chemotherapy method was very similar to the one previously described by Murray et al ( 199 la) . In brief, the regimen consisted of cisplatin 25 mg m-2 weekly for 9 weeks, vincristine 1 mg m-2 during weeks 1, 2, 4, 6 and 8, and doxorubicin 40 mg m-2 and etoposide 80 mg m-2 for 3 days during weeks 1, 3, 5, 7 and 9. Patients were randomly assigned to receive the CODE regimen with or without rhG-CSF (Kirin Brewery, Tokyo, Japan). rhG-CSF (50 gg m-2) was given by daily subcutaneous injection, except on the days of treatment. Treatment was delayed for one week or more if total leukocyte counts were less than I x 109 1-1 or if platelet counts were less than 30 x 109 1-' and then restarted with a full dose.
Thirty-two patients were treated with CODE with rhG-CSF and 31 with CODE without rhG-CSF (Table 1 ). The two groups were well matched with respect to the main clinical characteristics except for sex.
Patients were followed up regularly in the outpatient clinic for signs of relapse, toxicity and intercurrent illness. None of them were lost to follow-up. Survival curves were calculated using the method of Kaplan and Meier (Kaplan and Meier, 1958 ) and compared using the log-rank test (Peto et al, 1977) . The two groups were tested for differences in clinical attributes in 63 patients using the chi-square test or Fisher's exact test. The Statistical Application System (SAS, 1986) was used for multivariate analysis of prognostic variables in survival by use of a Cox proportional hazards model (Cox, 1972) . The size of the sample was calculated with a statistical power of 80% and a significance level of 5%, on the basis of an expected difference of 10% in the percentage of the dose intensity actually delivered versus scheduled dose intensity (70% in the control group vs 80% in the rhG-CSF group). 
RESULTS
In the rhG-CSF group, 16% of patients did not complete the intended programme, compared with 32% in the control group (P = 0.2099). A summary of the received protocol treatment is listed in Table 2 . Not surprisingly, the actual dose intensities of the individual drugs (except for vincristine) were significantly higher with the rhG-CSF regimen. Accordingly, the mean total received dose intensity for all drugs was significantly higher in the rhG-CSF group (84% of the projected dose for rhG-CSF patients vs 72% in the controls, P = 0.03). The use of rhG-CSF thus allowed an increase in the intensity of the delivered dose. Table 3 shows the results achieved using CODE chemotherapy. The median response durations for the rhG-CSF and the control groups were 33 and 22 weeks respectively (Figure 1 ). The difference was of border line significance (P = 0.0546).
Median follow-up of living patients was 42.3 months. At the time of this analysis 24 patients in the rhG-CSF group and 21 in the control group had died because of disease (Table 3) . Two in the rhG-CSF group and five in the control group died because of causes unrelated to this disease. The 45-week median survival time for all patients is superior to that reported in the literature (Aisner et al, 1983) . The median survival time in the rhG-CSF group was 59 weeks (95% confidence interval, CI, 45.6-90.9) compared with 32 weeks in the control group (95% CI, 24.4-41.4; P = 0.004) (Figure 2) . The 1-, 2-and 3-year actuarial survival rates in patients treated with rhG-CSF were 59.4%, 31.3% and 9.4% compared with 22.6%, 6.5% and 3.2%, respectively, in the patients treated without rhG-CSF. Univariate analysis of prognostic factors showed that treatment with rhG-CSF alone seemed to be associated with a statistically significant prognostic value (P = 0.0040). Liver metastases (P = 0.05 10) and serum CEA level (P = 0.0573) had a marginal effect. Sex, age, performance status, lactate dehydrogenase level and brain metastasis were not predictive of survival. Multivariate analysis according to prognostic factors clearly confirms that treatment with rhG-CSF is the only variable that significantly affects patient survival (Table 4) . (1997) 75(2) (-) and 32 weeks in the control group (----) respectively (P = 0.0004). The 1-, 2-and 3-year survival rates in the rhG-CSF group were 59.4%, 31.3% and 9.4% compared with 22.6%, 6.5% and 3.2% respectively, in the control group DISCUSSION This trial clearly demonstrated that the use of rhG-CSF in the CODE regimen was associated with an increase in delivered dose intensity (Table 2) . At the same time, the CODE plus rhG-CSF regimen was associated with a 27-week prolongation of median survival and an about fivefold increase in the 2-year survival rate (31.3% vs 6.5%) compared with the CODE-only group. The median survival time of 32 weeks in patients who received CODE alone is similar to that reported for extensive-stage patients (Aisner et al, 1983) . Therefore, this is the first randomized study in SCLC patients receiving rhG-CSF with chemotherapy to show that the administration of rhG-CSF results in significant prolongation of survival through the increase in cytotoxic dose-intensity. The results obtained here contrast sharply with those reported by Miles et al (1994) . In their randomized trial of weekly chemotherapy of cisplatin and etoposide alternating with ifosfamide and doxorubicin with or without rhG-CSF in SCLC, the proportion of patients experiencing dose reductions as the result of leukopenia was significantly higher in the control arm than in the rhG-CSF arm (P < 0.04). However, cycle delays because of leukopenia were similar in both arms. Furthermore, non-haematological toxicities, such as increased creatinine concentration, also prevented an increase in the received dose intensity. Therefore, administration of rhG-CSF did not allow a significant increase in the received dose intensity (84% in the rhG-CSF arm vs 82% in the control). The authors stated that the use of rhG-CSF may not be suitable for regimens in which myelosuppressive drugs are administered every week. Their approach is different from the one used in our trial. As the CODE regimen was designed by Murray et al (1991 a, b) to give alternating weekly cycles of myelosuppressive and non-myelosuppressive drugs, it may be possible to use rhG-CSF to alleviate chemotherapy-induced neutropenia. Another trial to test the contribution of rhG-CSF to increasing cytotoxic dose intensity in SCLC was reported by Woll et al (1995) , in which patients were randomized to receive vincristine, ifosfamide, carboplatin and etoposide alone or with rhG-CSF. The rhG-CSF group received a significantly higher dose-intensity than the control. The increase in dose-intensity in the rhG-CSF group was associated with a better 2-year survival rate (32% vs 15%), although the difference in median survival time (69 weeks vs 65 weeks) was not statistically significant.
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In conclusion, our results clearly demonstrate that, in patients with extensive-stage SCLC, CODE therapy with rhG-CSF prolongs the response duration and survival compared with CODE alone. Data obtained here with the use of rhG-CSF showing a 27-week improvement in median survival and a major increase in the 2-year survival rate (31.3% vs 6.5%) are very encouraging. However, most patients with this disease still die within 3 years; further improvements in systemic therapy are imperative.
